Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 21, Issue 2, 2014, Pages 111-120

  Baran, B ^a   Gulluoglu, M ^a   Soyer, O M ^a   Ormeci, A C ^a   Gokturk, S ^a   Evirgen, S ^a   Yesil, S ^a   Akyuz, F ^a   Karaca, C ^a   Demir, K ^a   Kaymakoglu, S ^a   Besisik, F ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

fibrosis progression; gamma glutamyl transferase; hepatitis C; nonresponder; treatment failure

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; VIRUS LOAD; BLOOD; COMPLICATION; CYTOCHEMISTRY; DISEASE COURSE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; PATHOLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C, CHRONIC; HISTOCYTOCHEMISTRY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 84891827753     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12127     Document Type: Article

References (28)

1. WHO. Hepatitis C. Global Alert and Response. Geneva, Switzerland: WHO, 2012.
2. Tozun N, Ozdogan O, Cakaloglu Y, et al,. A nationwide prevalence study and risk factors for hepatitis A, B, C and D infections in Turkey. Hepatology 2010; 52 (4): 697A.
3. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
4. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
5. Antaki N, Craxi A, Kamal S, et al,. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30 (3): 342-355.
6. Shiffman ML, Hofmann CM, Thompson EB, et al,. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26 (3): 780-785.
7. Sobesky R, Mathurin P, Charlotte F, et al,. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116 (2): 378-386.
8. McHutchison JG, Gordon SC, Schiff ER, et al,. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339 (21): 1485-1492.
9. Zeuzem S, Feinman SV, Rasenack J, et al,. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343 (23): 1666-1672.
10. Poynard T, McHutchison J, Manns M, et al,. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122 (5): 1303-1313.
11. Camma C, Di Bona D, Schepis F, et al,. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39 (2): 333-342.
12. Pockros PJ, Hamzeh FM, Martin P, et al,. Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology 2010; 52 (4): 1193-1200.
13. Goodman ZD, Stoddard AM, Bonkovsky HL, et al,. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009; 50 (6): 1738-1749.
14. Leroy V, De Traversay C, Barnoud R, et al,. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha. J Hepatol 2001; 35 (1): 120-126.
15. Shiratori Y, Imazeki F, Moriyama M, et al,. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132 (7): 517-524.
16. Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H,. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method. J Gastroenterol 2000; 35 (2): 105-111.
17. Kryczka W, Chrapek M, Paluch K, Zarebska-Michaluk D,. Progress of liver disease in chronic hepatitis C patients who failed antiviral therapy. Med Sci Monit 2003; 9 (Suppl. 3): 25-28.
18. Thein HH, Yi Q, Dore GJ, Krahn MD,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48 (2): 418-431.
19. EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-264.
20. Ishak K, Baptista A, Bianchi L, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22 (6): 696-699.
21. Kleiner DE, Brunt EM, Van Natta M, et al,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6): 1313-1321.
22. Poynard T, Bedossa P, Opolon P,. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349 (9055): 825-832.
23. Inagaki Y, Nemoto T, Kushida M, et al,. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 2003; 38 (4): 890-899.
24. Di Bisceglie AM, Shiffman ML, Everson GT, et al,. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359 (23): 2429-2441.
25. Widman A, Mendes-Correa MC, Zanoto A, et al,. Chronic hepatitis C: hepatic fibrosis evolution after ineffective specific treatment. Hepatogastroenterology 2008; 55 (82-83): 657-662.
26. Goodman ZD, Becker RL Jr, Pockros PJ, Afdhal NH,. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 2007; 45 (4): 886-894.
27. Berg T, Sarrazin C, Herrmann E, et al,. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37 (3): 600-609.
28. Akuta N, Suzuki F, Kawamura Y, et al,. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46 (3): 403-410.